Stocks · News reference
Sunflower State Health Plan, a subsidiary of Centene Corporation, received a 4 out of 5-star rating in the 2026 NCQA Medicaid Health Plan Ratings.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The U.S. government has intervened in a False Claims Act lawsuit alleging that Centene Corporation engaged in fraudulent Medicare Advantage enrollment practices.
Goldman Sachs has revised its price target for Centene Corporation, increasing it from $56 to $62.
Deutsche Bank has raised its price target for Centene Corporation from $85 to $87 while maintaining a Buy rating.
Truist has increased its price target for Centene Corporation from $80 to $82 while maintaining a Buy rating on the stock.
Missouri regulators finalized 2027 health insurance marketplace rates, with Ambetter from Centene's Home State Health Plan reporting the smallest average premium increase in the state at just under 10%.
Wells Fargo has maintained its Equal-Weight rating on Centene Corporation while increasing its price target from $69 to $75.